Lyra Therapeutics Inc. (LYRA)
0.12
-0.01 (-4.99%)
At close: Apr 01, 2025, 3:59 PM
0.12
3.20%
After-hours: Apr 01, 2025, 07:55 PM EDT
-4.99% (1D)
| Bid | 0.11 |
| Market Cap | 7.91M |
| Revenue (ttm) | 1.54M |
| Net Income (ttm) | -94.04M |
| EPS (ttm) | -1.43 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -0.19 |
| Analyst | Hold |
| Ask | 0.14 |
| Volume | 763,228 |
| Avg. Volume (20D) | 1,012,465 |
| Open | 0.13 |
| Previous Close | 0.13 |
| Day's Range | 0.12 - 0.13 |
| 52-Week Range | 0.12 - 6.29 |
| Beta | -0.18 |
About LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflam...
Industry Biotechnology
Sector Healthcare
IPO Date May 1, 2020
Employees 30
Stock Exchange NASDAQ
Ticker Symbol LYRA
Website https://lyratherapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for LYRA stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 940.80% from the latest price.
Stock Forecasts4 months ago
-28.11%
Lyra Therapeutics shares are trading lower after t...
Unlock content with
Pro Subscription
10 months ago
-19.46%
Lyra Therapeutics shares are trading lower on continued weakness after the company on Monday announced the ENLIGHTEN 1 trial did not meet its primary endpoint. Also, Jefferies downgraded the stock from Buy to Hold and lowered its price target from $10 to $0.5.
